[ad_1]
Mubadala Investment Company PJSC (Mubadala) and the UAE’s leading artificial intelligence and cloud computing company G42 signed an agreement to establish a world-class biopharmaceutical manufacturing park (biopharmaceutical park) in Abu Dhabi, which will take advantage of the global Advanced level-advanced vaccines and therapeutic products to strengthen the regional supply chain and promote the national diversification and economic growth agenda.
The Biopharmaceutical Park will invest in and establish a number of biopharmaceutical programs, leveraging the expertise of Mubadala Advanced Manufacturing Company and G42’s leading capabilities in artificial intelligence and cloud computing. The agreement reflects Mubadala’s ambition to develop a sustainable and resilient healthcare and life science ecosystem in Abu Dhabi, and further promotes socio-economic growth and diversification in the UAE, while improving the country’s and broader Middle East’s Health status.
Global supply shortages and limited advanced manufacturing activities in the region have led to biopharmaceuticals becoming a high-growth market (10% compound annual growth rate over the past five years) and Mubadala’s priority investment in the life sciences sector. The ability of biopharmaceutical products to solve previously incurable diseases also inspires confidence in the long-term and future growth potential of the market.
Commenting on the agreement, Musabbeh Al Kaabi, CEO of Mubadala UAE Investments, said: “By establishing this park in cooperation with G42 and our group companies, we are investing in innovation and strengthening Abu Dhabi’s fast-growing life science ecosystem. . Bringing cutting-edge manufacturing technologies to the UAE will not only strengthen our country’s biopharmaceutical supply chain and pandemic response, but also provide opportunities for local talent development and long-term, sustainable economic growth.”
Peng Xiao, CEO of G42 Group, said: “For many years, artificial intelligence and cloud computing technologies have matured. Ten years ago, these technologies were born in the technology industry, and now they have been widely used in applications that value speed, scalability, innovation, and flexibility. Numerous industries. Pharmaceutical and healthcare companies have plenty of opportunities to use artificial intelligence and cloud technology to improve their processes. We at G42 are very pleased to work with Mubadala to leverage our respective strengths to further accelerate the development of the UAE’s life science ecosystem.”
The world-class biopharmaceutical park will focus on the end-to-end manufacturing of the most advanced biologics and establish a major partnership with the Contract Manufacturing and Development Organization (CDMO). The CDMO model enables manufacturers to collaborate with multiple innovators, thereby reducing product risk and achieving economies of scale.
[ad_2]
Source link